Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine HCl ER for uremic pruritus in hemodialysis patients
2013-005625-22Phase 2Completed
- Sponsor
- Trevi Therapeutics
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nalbuphine in chronic kidney disease-associated pruritus (CKD-aP) (3 arms), sponsored by Trevi Therapeutics. Primary endpoint: Change in itch intensity on 0–10 Itch Numerical Rating Scale. Started Nov 2014; status: completed.
02
Drugs
nalbuphine
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on 2013-005625-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005625-22.